LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. GRI (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, Ph.D., President and Chief…Read More
GRI Bio Inc NASDAQ GRI to Participate in the Virtual Investor Summer Spotlight Series GRI Bio NASDAQGRI
